Lehtimäki Lauri, Arvidsson Monica, Erdemli Bora, Nan Cassandra, Nguyen Tra-My, Samant Aditya, Telg Gunilla
Faculty of Medicine and Health Technology, Tampere University; Allergy Centre, Tampere University Hospital, Tampere, Finland.
Respiratory Medicine and Allergy, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden.
Eur Clin Respir J. 2022 May 2;9(1):2066815. doi: 10.1080/20018525.2022.2066815. eCollection 2022.
Oral corticosteroids (OCS) are often prescribed to patients with asthma that remains uncontrolled with maintenance therapy. We performed a real-world analysis to describe the geographic distributions of patients with asthma and OCS dispensed in Nordic countries. This observational, retrospective study examined patient-level data from nationally prescribed drug registries from January to December 2018 for individuals aged ≥12 years in Denmark, Finland, and Sweden. Using an algorithm based on asthma treatment combinations defined by the Global Initiative for Asthma (GINA), we identified patients with asthma, those on GINA Step 4-5 treatments, and those being dispensed ≥2 courses of OCS and determined volumes of OCS dispensed to these patients over the 1-year analysis period. Data were plotted geographically within each country using colour-coded heat maps. The overall asthma prevalence rates were 7.4% in Denmark, 11.6% in Finland, and 8.1% in Sweden. In Denmark, Finland, and Sweden, respectively, the frequencies of patients on GINA Step 4-5 treatments were 19%, 15%, and 16%; among whom 10%, 23%, and 5% received ≥2 courses of OCS. The rates of patients on GINA Step 4-5 treatments who were dispensed OCS in each country were 23%, 30%, and 46%, of which 22%, 17%, and 10% were dispensed doses averaging ≥5 mg/day over the year. Heat maps revealed considerable heterogeneity in geographic densities of patients with asthma and OCS claims within each country. Taken together, these results demonstrate regional variations in estimated asthma severity, control, and OCS dispensed within and between countries. Patterns of medication use suggest that a high proportion of patients in Denmark, Finland, and Sweden are on GINA Step 4-5 treatments, many of whom are dispensed OCS; this poses a considerable corticosteroid burden to these patients. Geographic differences in medication use within and between Nordic countries may reflect variations in population characteristics and/or treatment approaches.
对于采用维持治疗后病情仍未得到控制的哮喘患者,医生常常会开具口服糖皮质激素(OCS)。我们开展了一项真实世界分析,以描述北欧国家哮喘患者及OCS配药情况的地理分布。这项观察性回顾研究分析了丹麦、芬兰和瑞典2018年1月至12月全国处方药登记处中年龄≥12岁个体的患者层面数据。我们使用基于全球哮喘防治创议(GINA)定义的哮喘治疗组合的算法,识别出哮喘患者、接受GINA 4-5级治疗的患者以及接受≥2个疗程OCS配药的患者,并确定了在1年分析期内这些患者的OCS配药量。数据在每个国家内使用彩色编码热图进行地理绘制。丹麦、芬兰和瑞典的总体哮喘患病率分别为7.4%、11.6%和8.1%。在丹麦、芬兰和瑞典,接受GINA 4-5级治疗的患者比例分别为19%、15%和16%;其中接受≥2个疗程OCS的患者比例分别为10%、23%和5%。各国接受GINA 4-5级治疗且配用OCS的患者比例分别为23%、30%和46%,其中在这一年中配用平均剂量≥5毫克/天的OCS的患者比例分别为22%、17%和10%。热图显示每个国家内哮喘患者和OCS配药申请的地理密度存在显著差异。综上所述,这些结果表明各国国内及之间在估计的哮喘严重程度、控制情况以及OCS配药方面存在区域差异。用药模式表明,丹麦、芬兰和瑞典有很大比例的患者接受GINA 4-5级治疗,其中许多患者配用了OCS;这给这些患者带来了相当大的皮质类固醇负担。北欧国家内部及之间用药情况的地理差异可能反映了人口特征和/或治疗方法的差异。